Drugs / CRC01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07364396 | Feb 2026 → Jun 2030 expected | lupus nephritis, systemic lupus erythematosus | Curocell Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Jiangsu HengRui Medicine Co., Ltd. | Results 2026 ASCO口头报告丨恒瑞ADC创新药瑞康曲妥珠单抗治疗HER2阳性结直肠癌Ⅲ期研究成果重磅发布 hengrui.com ↗
研究结果显示，与标准治疗相比，瑞康曲妥珠单抗在无进展生存期（PFS）、客观缓解率（ORR）等主要疗效指标上均展现出显著的临床获益，且安全性良好 1 。 |
| 2022-01-13 | AstraZeneca | Results AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU astrazeneca.com ↗
Additional Enhertu data at ASCO GI will include encore results from the DESTINY-CRC01 Phase II trial showing clinically meaningful activity in HER2-positive unresectable and/or metastatic colorectal cancer. |
| 2020-06-01 | Daiichi Sankyo | Results ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial daiichisankyo.com ↗
A disease control rate (DCR) of 83.0% was observed with a median progression-free survival (PFS) of 6.9 months. |
| 2020-05-29 | AstraZeneca | Results Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial astrazeneca.com ↗
The primary endpoint of confirmed objective response rate (ORR), assessed by independent central review, showed 45.3% of patients with HER2-positive (defined as IHC3+ or IHC2+/ISH+) advanced colorectal cancer treated with Enhertu monotherapy (6.4mg/kg) achieved a tumour response. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Jiangsu HengRui Medicine Co., Ltd. | 2026 ASCO口头报告丨恒瑞ADC创新药瑞康曲妥珠单抗治疗HER2阳性结直肠癌Ⅲ期研究成果重磅发布 hengrui.com ↗ |
| 2022-01-13 | AstraZeneca | AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU astrazeneca.com ↗ |
| 2020-06-01 | Daiichi Sankyo | ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial daiichisankyo.com ↗ |
| 2020-05-29 | AstraZeneca | Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial astrazeneca.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRC01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07364396 ↗ |
| Modality | Cell therapy | “an investigational autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy” NCT07364396 ↗ |
| Route | Intravenous | “Administered as a single intravenous infusion.” NCT07364396 ↗ |
| Target | CD19 | “anti-CD19 chimeric antigen receptor (CAR)” NCT07364396 ↗ |